Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
Ⅱ型 CD20 抗体 GA101（奥比妥珠单抗）与利妥昔单抗和奥法木单抗在体外和异种移植模型中的临床前活性比较
期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-12-1182
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo
